What is the recommended dosing regimen for fluvoxamine, including initial dose, titration schedule, maximum dose, and adjustments for hepatic impairment and elderly patients?

Fluvoxamine Dosing Guidelines

Adult Dosing for OCD and Depression

For adults, start fluvoxamine at 50 mg once daily at bedtime, then increase by 50 mg increments every 4–7 days as tolerated to a therapeutic range of 100–300 mg/day, with doses above 100 mg divided into two administrations (larger dose at bedtime). 1

• The therapeutic dose range established in controlled trials is 100–300 mg per day, with the maximum not exceeding 300 mg/day 2, 1
• When total daily dose exceeds 100 mg, administer in two divided doses with the larger portion at bedtime to minimize side effects 1
• Titration should occur every 4–7 days based on tolerability and response 1
• Research supports that 100–150 mg daily produces significantly better response rates (73.7%) compared to 50–75 mg daily (47.1%) 3
• Therapeutic response typically becomes evident by week 6, with maximal improvement by week 12 2, 4

Pediatric Dosing (Ages 8–17 Years)

Start children and adolescents at 25 mg once daily at bedtime, then increase by 25 mg increments every 4–7 days as tolerated. 1

• Maximum dose for children up to age 11: 200 mg/day 1
• Maximum dose for adolescents: 300 mg/day (same as adults) 1
• When total daily dose exceeds 50 mg, divide into two doses with the larger portion at bedtime 1
• Female children may achieve therapeutic effect at lower doses due to 1.5- to 2.7-fold higher drug exposure compared to males 1
• Titration intervals of 1–2 weeks are recommended due to fluvoxamine's relatively short half-life in this population 2

Elderly and Hepatically Impaired Patients

Elderly patients and those with hepatic impairment require reduced initial doses and slower titration due to 50% reduction in clearance. 1, 5

• In elderly subjects, peak concentrations are 40% higher and elimination half-life is prolonged to 17.4–25.9 hours (versus 13.6–15.6 hours in young adults) 1, 5
• Oral clearance is halved in elderly patients (1.12 vs. 2.25 L/h/kg), with area under the curve nearly three times higher 5
• Start with lower doses (e.g., 25 mg daily) and titrate more gradually in this population 1
• Hepatic dysfunction reduces fluvoxamine clearance by approximately 30%, necessitating dose modification 1, 6

Renal Impairment

No dose adjustment is required for renal impairment, as fluvoxamine elimination is primarily hepatic with only 2–3% excreted unchanged in urine. 1, 6, 7

• Chronic heart failure does not significantly affect fluvoxamine pharmacokinetics in elderly patients 5

Critical Drug Interaction Considerations

Fluvoxamine potently inhibits CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6, creating extensive drug-drug interaction potential. 2, 4

• Absolute contraindication: concurrent MAOI use; require a 14-day washout period when switching between fluvoxamine and MAOIs 2
• Avoid co-administration with other serotonergic agents due to serotonin syndrome risk 2, 4
• For patients with Alzheimer's-related depression, exercise caution when co-administering alprazolam or triazolam due to interaction risk 8, 2
• CYP1A2 substrates (theophylline, caffeine) and CYP3A4 substrates (statins, calcium-channel blockers) may have significantly increased plasma concentrations 4

Discontinuation Protocol

Taper fluvoxamine gradually over 10–14 days rather than stopping abruptly to minimize discontinuation syndrome. 2, 4, 1

• Abrupt cessation can cause withdrawal symptoms including dizziness, fatigue, nausea, sensory disturbances ("electric shock" sensations), headache, and irritability 2, 4
• If intolerable symptoms occur during taper, resume the previous dose and decrease more gradually 1
• Fluvoxamine's mean half-life of 15 hours (range 9–28 hours) makes it more prone to discontinuation symptoms than longer-acting SSRIs 6

Safety Monitoring Requirements

Monitor intensively for suicidality, especially during the first months of therapy and after dose changes, per FDA black-box warning. 2, 4

• Serotonin syndrome surveillance is critical during the first 24–48 hours of any dose change or when adding serotonergic medications 2, 4
• Key warning signs include: mental-status changes (confusion, agitation), neuromuscular hyperactivity (tremor, clonus, hyperreflexia), and autonomic instability (tachycardia, hypertension, diaphoresis) 4
• Nausea is the most common cause of early discontinuation; mitigation strategies include starting at low doses, slow titration, taking with food, and divided dosing with the larger portion at bedtime 2, 4
• Conduct clinical review within 1–2 weeks after initiating therapy and maintain regular follow-up 4

Special Populations: Pregnancy Third Trimester

Consider tapering fluvoxamine during the third trimester due to risk of neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding. 1

• Carefully weigh potential risks versus benefits when treating pregnant women in the third trimester 1

Maintenance Therapy

Continue fluvoxamine at the lowest effective dosage for responding patients, with periodic reassessment to determine ongoing need for treatment. 1

• Although efficacy beyond 10 weeks has not been documented in controlled trials, OCD is a chronic condition that may warrant long-term treatment 1
• If adequate response is not achieved after 6–8 weeks at therapeutic doses, consider alternative treatment strategies 2, 4